Purpose
This first-in-human (FIH) dose-escalation and dose-validation/expansion study will assess ziftomenib (KO-539), a menin-MLL(KMT2A) inhibitor, in patients with relapsed or refractory acute myeloid leukemia (AML).
Full Title
A Phase 1/2A First in Human Study of the Menin-MLL(KMT2A) Inhibitor
KO-539 in Patients with Relapsed or Refractory Acute Myeloid Leukemia
ClinicalTrials.Gov ID
NCT04067336
To inquire about participating in these studies, call 1-800-ROSWELL (1-800-767-9355) or e-mail askroswell@roswellpark.org.